MOTHAFFAR RIMAWI to Aromatase Inhibitors
This is a "connection" page, showing publications MOTHAFFAR RIMAWI has written about Aromatase Inhibitors.
Connection Strength
1.714
-
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Res Treat. 2019 Sep; 177(2):427-435.
Score: 0.642
-
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. J Clin Oncol. 2018 10 01; 36(28):2826-2835.
Score: 0.605
-
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clin Breast Cancer. 2018 02; 18(1):78-87.
Score: 0.143
-
Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28.
Score: 0.118
-
Aromatase inhibitor adverse effects: are we sweeping them under the rug? J Clin Oncol. 2014 Nov 20; 32(33):3779.
Score: 0.115
-
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis. Clin Cancer Res. 2023 04 14; 29(8):1468-1476.
Score: 0.052
-
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. J Clin Oncol. 2019 01 20; 37(3):178-189.
Score: 0.039